NV-1NCE
5.1.2023 15:31:41 CET | Business Wire | Press release
1NCE, a global IoT connectivity and software company, today announced the creation of its software business unit in conjunction with the Consumer Electronics Show launch of 1NCE OS – IoT software offering powerful developer tools and device control to make IoT even more accessible.
The software tools are an integral part of 1NCE’s Lifetime Flat service and are available complimentary to 1NCE customers.
1NCE OS is a foundational element of the company’s ambitious goal: to cement 1NCE’s standing as the preeminent destination for accessible IoT. It’s designed for easy integration of 1NCE’s connectivity and software features into IoT projects of any scale, for new and existing projects alike. Using 1NCE OS for device and cloud integration, customers can accelerate time-to-market for IoT projects by months. One of 1NCE’s core principles is that customer data isn’t to be monetized and used to sell additional services. Instead, 1NCE is transparent about turning data into tools that are included in the global lifetime flat rate.
Features available at launch:
- Device Authentication: The process of setting up a secure and automated solution usually requires a complicated and error-prone onboarding process. 1NCE OS makes it simple: customers just solder the secure SIM into their device just like any other hardware piece and that’s it – delivering better authentication and integration of uniquely identified devices into IoT projects.
- IoT Integrator: Reliably connecting devices to the cloud can be complex, but 1NCE’s managed protocol translation uses open industry standards (UDP, CoAP, LwM2M, AWS IoT Core, Webhooks) to give customers the free and full flexibility they demand.
- Device Inspector: The time-intensive and costly process of sending technicians into the field to monitor and service devices is significantly reduced using advanced remote access to device states and recent telemetry.
- Device Locator: Network based positioning helps users locate devices even without GPS.
- Energy Saver: The inherent challenges of battery-powered devices make power usage a high priority, and 1NCE’s optimized payload transmission can increase battery life by up to 50 percent.
Fredrik Stålbrand of Berg Insights said: “1NCE OS and 1NCE’s product roadmap look very compelling. Our view is that the IoT connectivity market will increasingly move towards digitalized sales and delivery. SIMs will be pre-installed in chipsets, while connectivity management is increasingly being controlled by SaaS applications. Customers expect simple, digital experiences throughout the product lifecycle. 1NCE is clearly at the forefront of this development.”
Ivo Rook, Chief Operating Officer at 1NCE: “1NCE flips the script for customers – we don’t monetize their data for a few extra dollars because our customers’ data is theirs and theirs alone. 1NCE’s move into software allows us to boost our customers’ ideas not just when they need connectivity, but from the outset of their projects and all the way through a device’s lifecycle. IoT connectivity and software for life for a single fee, and that’s it.”
Fifty percent of failed IoT projects falter in the pilot stage. For new IoT projects, 1NCE makes it easy to experiment early without major expenditures that can kill a project. Customers connect sensors across the globe at a fraction of the cost of the traditional price of network operators, and now with 1NCE OS, they gain access to software tools that accelerate time-to-market without vendor lock-in or paying for unnecessary features packaged into most IoT platforms. And for IoT projects that are already up and running, 1NCE’s combination of connectivity and software delivers trusted, production-grade solutions for continuous improvement and optimization.
The majority of IoT projects require multinational deployments, but few network operators have the capability to truly meet cross-border demands. The 1NCE Lifetime Flat service is industry-disruptive but simple: for $10/€10, customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. More than 10,000 customers worldwide already trust 1NCE with more than 15 million managed connections.
The company’s ability to deliver affordable and reliable IoT, and its rapid global expansion to 153 markets from 106 at the beginning of the year, helped 1NCE earn two prestigious awards recently: Honorable Mention on Fast Company’s list of the Next Big Things in Tech and top prize for the most outstanding use case in “innovative IoT” (in partnership with Flashnet) at Light Reading’s 18th annual Leading Lights.
More information about 1NCE OS can be found here and customers can get started with 1NCE at the company’s online shop and the AWS Marketplace. Customer support is available in 14 languages.
About 1NCE
1NCE is the only connectivity and software company providing IoT at a lifetime global flat rate. Our mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 150+ countries, 1NCE turns connectivity into electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. The company, founded in 2017 by CEO Alexander P. Sator together with Deutsche Telekom AG, is headquartered in Cologne, Germany and has 250+ staff across 20 countries. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
